One million shares | INSM Message Board Posts


Insmed Incorporated

  INSM website

INSM   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  59802 of 60134  at  10/22/2021 4:35:13 PM  by

tocentsworth

The following message was updated on 10/25/2021 10:01:41 AM.

 In response to msg 59799 by  insmhistorian
view thread

Re: One million shares

I find Zacks' pretty useless when it is following young companies with growing revenues, but much faster growing expenses. Insmed has only one "refractory" product (i.e. Arikayce), and its global revenue growth has been slowed by the pandemic. Still, with $928. M in the bank in late June, Insmed's expenses will be growing significantly from here, with its 4 pillared pipeline having to traverse through Phase III trials before applicable drug applications can even be submitted.
The short-term focus here should be on Arikayce global revenue growth, and pipeline progress, not earnings. JMHO.
 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 1  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...